Switch theme
Sign up to access all valuation multiples
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
1999
818
LTM Revenue $173M
LTM EBITDA -$75.9M
$138M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Standard BioTools has a last 12-month revenue (LTM) of $173M and a last 12-month EBITDA of -$75.9M.
In the most recent fiscal year, Standard BioTools achieved revenue of $174M and an EBITDA of -$118M.
Standard BioTools expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Standard BioTools valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $173M | XXX | $174M | XXX | XXX | XXX |
| Gross Profit | $87.2M | XXX | $84.3M | XXX | XXX | XXX |
| Gross Margin | 51% | XXX | 48% | XXX | XXX | XXX |
| EBITDA | -$75.9M | XXX | -$118M | XXX | XXX | XXX |
| EBITDA Margin | -44% | XXX | -68% | XXX | XXX | XXX |
| EBIT | -$150M | XXX | -$135M | XXX | XXX | XXX |
| EBIT Margin | -87% | XXX | -77% | XXX | XXX | XXX |
| Net Profit | -$147M | XXX | -$139M | XXX | XXX | XXX |
| Net Margin | -85% | XXX | -80% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Standard BioTools's stock price is $1.
Standard BioTools has current market cap of $365M, and EV of $138M.
See Standard BioTools trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $138M | $365M | XXX | XXX | XXX | XXX | $-0.40 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Standard BioTools has market cap of $365M and EV of $138M.
Standard BioTools's trades at 0.8x EV/Revenue multiple, and -1.2x EV/EBITDA.
Equity research analysts estimate Standard BioTools's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Standard BioTools has a P/E ratio of -2.5x.
See valuation multiples for Standard BioTools and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $365M | XXX | $365M | XXX | XXX | XXX |
| EV (current) | $138M | XXX | $138M | XXX | XXX | XXX |
| EV/Revenue | 0.8x | XXX | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | -1.8x | XXX | -1.2x | XXX | XXX | XXX |
| EV/EBIT | -0.9x | XXX | -1.0x | XXX | XXX | XXX |
| EV/Gross Profit | 1.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.5x | XXX | -2.6x | XXX | XXX | XXX |
| EV/FCF | -1.1x | XXX | -0.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialStandard BioTools's last 12 month revenue growth is 3%
Standard BioTools's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.
Standard BioTools's rule of 40 is -48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Standard BioTools's rule of X is -37% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Standard BioTools and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | -44% | XXX | -68% | XXX | XXX | XXX |
| EBITDA Growth | -42% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -48% | XXX | -65% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -37% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 36% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 126% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Standard BioTools acquired XXX companies to date.
Last acquisition by Standard BioTools was XXXXXXXX, XXXXX XXXXX XXXXXX . Standard BioTools acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Standard BioTools founded? | Standard BioTools was founded in 1999. |
| Where is Standard BioTools headquartered? | Standard BioTools is headquartered in United States of America. |
| How many employees does Standard BioTools have? | As of today, Standard BioTools has 818 employees. |
| Who is the CEO of Standard BioTools? | Standard BioTools's CEO is Dr. Michael Egholm, PhD. |
| Is Standard BioTools publicy listed? | Yes, Standard BioTools is a public company listed on NAS. |
| What is the stock symbol of Standard BioTools? | Standard BioTools trades under LAB ticker. |
| When did Standard BioTools go public? | Standard BioTools went public in 2011. |
| Who are competitors of Standard BioTools? | Similar companies to Standard BioTools include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Standard BioTools? | Standard BioTools's current market cap is $365M |
| What is the current revenue of Standard BioTools? | Standard BioTools's last 12 months revenue is $173M. |
| What is the current revenue growth of Standard BioTools? | Standard BioTools revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Standard BioTools? | Current revenue multiple of Standard BioTools is 0.8x. |
| Is Standard BioTools profitable? | Yes, Standard BioTools is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Standard BioTools? | Standard BioTools's last 12 months EBITDA is -$75.9M. |
| What is Standard BioTools's EBITDA margin? | Standard BioTools's last 12 months EBITDA margin is -44%. |
| What is the current EV/EBITDA multiple of Standard BioTools? | Current EBITDA multiple of Standard BioTools is -1.8x. |
| What is the current FCF of Standard BioTools? | Standard BioTools's last 12 months FCF is -$124M. |
| What is Standard BioTools's FCF margin? | Standard BioTools's last 12 months FCF margin is -72%. |
| What is the current EV/FCF multiple of Standard BioTools? | Current FCF multiple of Standard BioTools is -1.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
